As per the current market research conducted by the CMI Team, the global Lung Cancer Liquid Biopsy Market size is expected to record a CAGR of 10.2% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 504.8 Million. By 2033, the valuation is anticipated to reach USD 1,210 Million.

Lung Cancer Liquid Biopsy Market: Growth Factors and Dynamics

  • Increasing Incidence of Lung Cancer: Lung cancer remains one of the leading causes of cancer-related deaths globally. The rising incidence of lung cancer, especially non-small cell lung cancer (NSCLC), is a primary driver for the growth of the liquid biopsy market. Liquid biopsy offers a less invasive method for the detection and monitoring of lung cancer compared to traditional tissue biopsies.
  • Advancements in Liquid Biopsy Technologies: Technological advancements in liquid biopsy techniques, such as circulating tumor DNA (ctDNA) analysis, circulating tumor cells (CTCs), and exosome analysis, have significantly improved the sensitivity and accuracy of detecting lung cancer biomarkers. These advancements have expanded the clinical utility of liquid biopsies in early detection, treatment selection, and monitoring of disease progression.
  • Shift Towards Personalized Medicine: The paradigm shift towards personalized medicine and targeted therapies has fueled the demand for companion diagnostic tests, including liquid biopsy assays. Liquid biopsies enable the molecular profiling of tumors, facilitating the identification of specific genetic mutations (e.g., EGFR, ALK, ROS1) that can guide treatment decisions and improve patient outcomes.
  • Rising Adoption of Liquid Biopsy in Clinical Practice: Liquid biopsy has gained acceptance in clinical practice due to its non-invasive nature, ability to provide real-time monitoring of tumor dynamics, and potential to overcome the limitations of tissue biopsies, such as tissue heterogeneity and sampling bias. Healthcare providers increasingly integrate liquid biopsy-based testing into routine clinical workflows for patients with lung cancer.
  • Expanding Research and Development Activities: Pharmaceutical companies, diagnostic firms, and academic institutions are actively investing in research and development initiatives to enhance the capabilities of liquid biopsy technologies for lung cancer diagnosis and management. Collaborative efforts aim to validate novel biomarkers, improve assay sensitivity, and develop standardized protocols for liquid biopsy testing.
  • Regulatory Support and Reimbursement Policies: Regulatory agencies, such as the FDA and EMA, have shown a willingness to expedite the approval and regulatory clearance of liquid biopsy-based tests for lung cancer diagnosis and monitoring. Additionally, the establishment of reimbursement policies by healthcare payers has encouraged the adoption of liquid biopsy assays by healthcare providers, ensuring financial sustainability and accessibility for patients.

Get Free Sample Copy @ https://www.custommarketinsights.com/request-for-free-sample/?reportid=45654

Lung Cancer Liquid Biopsy Market: Partnership and Acquisitions

  • In 2022, Illumina, Inc. partnered with Bristol Myers Squibb to advance companion diagnostics for precise oncology. Their collaboration focuses on enhancing therapy selection through innovations like the TSO 500 ctDNA liquid biopsy assay, offering comprehensive genomic profiling to guide personalized treatment decisions.
  • In 2022, The US FDA approved 177Lu-PSMA-617, a novel treatment for metastatic prostate cancer. This targeted therapy, utilizing lutetium-177, signifies a significant advancement in addressing the needs of patients with metastatic prostate cancer, offering new hope in their treatment journey.

Lung Cancer Liquid Biopsy Market: COVID-19 Analysis

The COVID-19 pandemic has had a significant impact on the Lung Cancer Liquid Biopsy Market, with the industry experiencing both positive and negative effects. Here are some of the key impacts:

  • Disruption in Healthcare Services: The COVID-19 pandemic led to significant disruptions in healthcare services globally, including routine cancer screenings and elective procedures. Many patients postponed or cancelled their appointments for lung cancer screening and monitoring, resulting in reduced demand for liquid biopsy testing.
  • Supply Chain Disruptions: The pandemic disrupted supply chains for diagnostic reagents, laboratory equipment, and consumables, affecting the production and availability of liquid biopsy kits and assays. Delays in procurement and distribution of essential components hampered the capacity of laboratories to perform liquid biopsy testing efficiently.
  • Resumption of Screening and Diagnostic Services: With the gradual easing of pandemic-related restrictions and the rollout of vaccination programs, healthcare facilities have resumed routine screening and diagnostic services for lung cancer. Increased awareness campaigns and outreach efforts aim to encourage patients to prioritize their lung cancer screenings, including the adoption of liquid biopsy as a non-invasive testing option.

List of the prominent players in the Lung Cancer Liquid Biopsy Market:

  • Guardant Health Inc.
  • Hoffmann-La Roche Ltd
  • Biocept Inc.
  • QIAGEN N.V.
  • Natera Inc.
  • Sysmex Corporation
  • Trovagene Inc.
  • Bio-Rad Laboratories Inc.
  • Genomic Health Inc.
  • Pathway Genomics Corporation
  • Resolution Bioscience Inc.
  • Inivata Ltd.
  • OncoCyte Corporation
  • Biodesix Inc.
  • Menarini Silicon Biosystems S.p.A.
  • Others

Table of Contents: https://www.custommarketinsights.com/report/lung-cancer-liquid-biopsy-market/#table-of-contents

About Us:

Custom Market Insights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains.

Custom Market Insights provides a one-stop solution for data collection to investment advice. The expert analysis of our company digs out essential factors that help to understand the significance and impact of market dynamics. The professional experts apply clients inside on the aspects such as strategies for future estimation fall, forecasting or opportunity to grow, and consumer survey.

Contact Us:

USA Corporate Office

CMI Consulting LLC

1333, 701 Tillery Street Unit 12, Austin, TX, Travis, US, 78702
Sales & Support +1 801 639 9061

Email : support@custommarketinsights.com

Website : https://www.custommarketinsights.com/